US2006063838A1PendingUtilityA1

Activators of peroxisome proliferator-activated receptors

46
Assignee: NAGASAKI PREFECTURAL GOVERNMENPriority: Apr 24, 2000Filed: Nov 15, 2005Published: Mar 23, 2006
Est. expiryApr 24, 2020(expired)· nominal 20-yr term from priority
Inventors:Yoshihiro ShidojiNaoto Ishibashi
A61P 3/10A61P 3/06A61P 43/00A61K 31/202A61K 31/20
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Activators of peroxisome proliferator-activated receptors comprising a polyprenyl compound, preferably (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid, as an active ingredient, and medicaments for preventive and/or therapeutic treatment of hyperlipidemia, non-insulin dependent diabetes mellitus or the like comprising a polyprenyl compound as an active ingredient.

Claims

exact text as granted — not AI-modified
1 . A method of preventing or treating hyperlipidemia, wherein the method comprises administering a preventively or therapeutically effective amount of at least one polyprenyl compound to a patient in need thereof, the at least one polyprenyl compound comprising 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid.  
     
     
         2 . The method of  claim 1 , wherein the at least one polyprenyl compound comprises (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid.  
     
     
         3 . The method of  claim 1 , wherein the at least one polyprenyl compound is in an orally administrable form.  
     
     
         4 . A method of preventing or treating non-insulin dependent diabetes mellitus, wherein the method comprises administering a preventively or therapeutically effective amount of at least one polyprenyl compound to a patient in need thereof, the at least one polyprenyl compound comprising 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid.  
     
     
         5 . The method of  claim 4 , wherein the at least one polyprenyl compound comprises (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid.  
     
     
         6 . The method of  claim 4 , wherein the at least one polyprenyl compound is in an orally administrable form.  
     
     
         7 . A method of activating a peroxisome proliferator-activated receptor (PPAR), wherein the method comprises administering a PPAR activating amount of at least one polyprenyl compound to a patient in need of such activation, the at least one polyprenyl compound comprising 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid.  
     
     
         8 . The method of  claim 7 , wherein the at least one polyprenyl compound comprises (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid.  
     
     
         9 . The method of  claim 7 , wherein the at least one polyprenyl compound is in an orally administrable form.  
     
     
         10 . The method of  claim 7 , wherein the PPAR comprises PPARα.  
     
     
         11 . The method of  claim 7 , wherein the PPAR comprises PPARγ.

Join the waitlist — get patent alerts

Track US2006063838A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.